Koninklijke Philips (ENXTAM:PHIA) Following New Monitoring Deals Still Looks Undervalued
What the new monitoring partnerships mean for Koninklijke Philips stock
Koninklijke Philips (ENXTAM:PHIA) has moved to widen its connected care footprint by partnering with several wearable and out of hospital monitoring providers, aiming to link more patient data into its existing ecosystem.
The collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare extend Philips monitoring reach from hospital to home and may influence how investors think about its Connected Care and Diagnosis & Treatment segments.
See our latest analysis for Koninklijke Philips.
Against this backdrop of new monitoring partnerships, Koninklijke Philips’ recent share price return has been mixed, with a 7 day gain of 2.64% and a 90 day share price return of 5.33%. The 1 year total shareholder return sits at 5.25% and the 3 year total shareholder return at 34.96%, hinting at steady but not explosive momentum around the current €23.31 level.
If connected care is on your radar, it can help to widen the lens beyond a single stock and look at other healthcare focused AI opportunities through the 130 healthcare AI stocks
Koninklijke Philips now sits at about €23.31 with fresh connected care partnerships in play. Is that a fair price to pay today, or does it make more sense to wait for a cheaper entry before committing new capital?
Most Popular Narrative: 16.5% Undervalued
Compared with the last close at €23.31, the most followed narrative for Koninklijke Philips sees fair value closer to €27.93. This frames the new monitoring partnerships in a wider earnings and margin story.
Analysts are assuming Koninklijke Philips's revenue will grow by 4.0% annually over the next 3 years. Analysts assume that profit margins will increase from 5.5% today to 8.2% in 3 years time.
Want to see how a modest revenue line and a bigger profit slice combine into that higher fair value? The narrative leans on steadier earnings, thicker margins and a valuation multiple that still prices in discipline. Curious which assumption really moves the model?
Result: Fair Value of €27.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to factor in risks such as ongoing FDA scrutiny around Philips Respironics, as well as tariff or procurement pressures that could squeeze margins and slow orders.
Find out about the key risks to this Koninklijke Philips narrative.
Next Steps
If this mixed picture around Koninklijke Philips leaves you undecided, take a moment to review the key risks and potential upsides yourself. You can move quickly from headline impressions to a more balanced view by checking the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Koninklijke Philips?
If Koninklijke Philips has your attention, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that could fit your goals.
- Target potential upside with value focused ideas by checking out 262 high quality undervalued stocks.
- Strengthen your income stream by reviewing stocks in the 440 dividend fortresses.
- Prioritise resilience by scanning companies in the 297 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com